Explore pharmaceutical companies to know 2026 delivering innovative pharmacy solutions and improving patient care across the U.S.

The proposed acquisition would hand Servier a couple experimental drugs in human testing as well as Ojemda, an approved ...

Evotec stock remains a speculative "Buy" with a $9/share price target. Here's what investors need to know about EVO.

METI & TSE select Chugai for the “2026 KENKO Investment for Health” for the third consecutive year: Tokyo Tuesday, March 10, 2026, 15:00 Hrs [IST] Chugai Pharmaceutical Co., L ...

The San Antonio group responsible for recruiting and retaining companies missed its job targets for the past five years. Its ...

Sell on Novo Nordisk A/S: slowing growth, downgraded 2025 guidance, rising GLP-1 competition, pricing/patent risks, limited ...

Merck said on Monday it would split its business into two, creating ⁠a division for its cancer franchise while grouping its ​non-oncology treatments separately.

The global weight-loss drug market is entering a new phase, driven by the arrival of oral options, looming generic rivals and falling U.S. prices for blockbuster treatments from Eli Lilly and Novo ...

Research has shown that financial conflicts of interest (COIs) are a common issue in medicine and psychiatry, with a 2020 ...

Commission defends itself in court against claims that it should have revealed more information about its contracts with Big Pharma.

Considering the good news, is Vertex heading to $600? Let's find out.